A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis

NCT01899729 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: IMO-8400 Regimen 1
DRUG: IMO-8400 Regimen 2
DRUG: IMO-8400 Regimen 3
DRUG: Saline Placebo
DRUG: IMO-8400 Regimen 4

Sponsor

Idera Pharmaceuticals, Inc.